Inflammation, atherosclerosis, and coronary artery disease.
暂无分享,去创建一个
Ildikó Kriszbacher | József Bódis | I. Kriszbacher | M. Koppán | J. Bódis | G. Hansson | Miklós Koppán
[1] J. Nilsson. CRP--marker or maker of cardiovascular disease? , 2005, Arteriosclerosis, thrombosis, and vascular biology.
[2] R. Kronmal,et al. Azithromycin for the secondary prevention of coronary events. , 2005, The New England journal of medicine.
[3] A. Skene,et al. Antibiotic treatment of Chlamydia pneumoniae after acute coronary syndrome. , 2005, The New England journal of medicine.
[4] Paul Schoenhagen,et al. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. , 2005, The New England journal of medicine.
[5] C. Lines,et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. , 2005, The New England journal of medicine.
[6] L. Glimcher,et al. T-bet deficiency reduces atherosclerosis and alters plaque antigen-specific immune responses. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[7] M. Pfeffer,et al. C-reactive protein levels and outcomes after statin therapy. , 2005, The New England journal of medicine.
[8] M. Ehrenstein,et al. Statins for atherosclerosis--as good as it gets? , 2005, The New England journal of medicine.
[9] P. Shah,et al. Immunomodulation of atherosclerosis: implications for vaccine development. , 2004, Arteriosclerosis, thrombosis, and vascular biology.
[10] Yuzhi Zhang,et al. Distinct endothelial phenotypes evoked by arterial waveforms derived from atherosclerosis-susceptible and -resistant regions of human vasculature. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[11] T. V. van Berkel,et al. Blocking endothelial adhesion molecules: a potential therapeutic strategy to combat atherogenesis , 2004, Current opinion in lipidology.
[12] C. Söderberg-Nauclér,et al. Human Cytomegalovirus Inhibits Cytokine-Induced Macrophage Differentiation , 2004, Journal of Virology.
[13] D. Broide,et al. IL-5 links adaptive and natural immunity specific for epitopes of oxidized LDL and protects from atherosclerosis. , 2004, The Journal of clinical investigation.
[14] P. Libby,et al. Lysosomal Cysteine Proteases in Atherosclerosis , 2004, Arteriosclerosis, thrombosis, and vascular biology.
[15] Richard T. Lee,et al. Th2-predominant inflammation and blockade of IFN-gamma signaling induce aneurysms in allografted aortas. , 2004, The Journal of clinical investigation.
[16] B. Hedblad,et al. Fatality of Future Coronary Events Is Related to Inflammation-Sensitive Plasma Proteins: A Population-Based Prospective Cohort Study , 2004, Circulation.
[17] M. Margaglione,et al. Low-grade inflammation may play a role in the etiology of the metabolic syndrome in patients with coronary heart disease: the HIFMECH study. , 2004, Metabolism: clinical and experimental.
[18] R. Madhok,et al. Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebo-controlled trial , 2004, The Lancet.
[19] Vilmundur Gudnason,et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. , 2004, The New England journal of medicine.
[20] K. Moore,et al. Reduced atherosclerosis in MyD88-null mice links elevated serum cholesterol levels to activation of innate immunity signaling pathways , 2004, Nature Medicine.
[21] F. Mach,et al. Antagonism of RANTES Receptors Reduces Atherosclerotic Plaque Formation in Mice , 2004, Circulation research.
[22] H. Ljunggren,et al. CD1d-dependent Activation of NKT Cells Aggravates Atherosclerosis , 2004, The Journal of experimental medicine.
[23] S. Szabo,et al. Molecular mechanisms regulating Th1 immune responses. , 2003, Annual review of immunology.
[24] R. Flavell,et al. Disruption of TGF-β signaling in T cells accelerates atherosclerosis , 2003 .
[25] E. Topol,et al. Prognostic value of myeloperoxidase in patients with chest pain. , 2003, The New England journal of medicine.
[26] N. Leitinger. Oxidized phospholipids as modulators of inflammation in atherosclerosis , 2003, Current opinion in lipidology.
[27] J. Witztum,et al. Oxidized low density lipoprotein and innate immune receptors , 2003, Current opinion in lipidology.
[28] D. Herrington,et al. Matrix metalloproteinases: a review of their structure and role in acute coronary syndrome. , 2003, Cardiovascular research.
[29] Christopher M O'Connor,et al. Azithromycin for the secondary prevention of coronary heart disease events: the WIZARD study: a randomized controlled trial. , 2003, JAMA.
[30] S. Akira,et al. Reduced atherosclerosis in interleukin-18 deficient apolipoprotein E-knockout mice. , 2003, Cardiovascular research.
[31] S. Frøland,et al. Interleukin-7–Mediated Inflammation in Unstable Angina: Possible Role of Chemokines and Platelets , 2003, Circulation.
[32] Qingbo Xu,et al. Cross-Reactive B-Cell Epitopes of Microbial and Human Heat Shock Protein 60/65 in Atherosclerosis , 2003, Arteriosclerosis, thrombosis, and vascular biology.
[33] J. Witztum,et al. Pneumococcal vaccination decreases atherosclerotic lesion formation: molecular mimicry between Streptococcus pneumoniae and oxidized LDL , 2003, Nature Medicine.
[34] P. Shah,et al. Inhibition of Atherosclerosis in ApoE-Null Mice by Immunization with ApoB-100 Peptide Sequences , 2003, Arteriosclerosis, thrombosis, and vascular biology.
[35] P. Arner. The adipocyte in insulin resistance: key molecules and the impact of the thiazolidinediones , 2003, Trends in Endocrinology & Metabolism.
[36] P. Shah,et al. Effect of short-term treatment with azithromycin on recurrent ischaemic events in patients with acute coronary syndrome in the Azithromycin in Acute Coronary Syndrome (AZACS) trial: a randomised controlled trial , 2003, The Lancet.
[37] I. Charo,et al. Decreased atherosclerosis in CX3CR1-/- mice reveals a role for fractalkine in atherogenesis. , 2003, The Journal of clinical investigation.
[38] Peter Libby,et al. Chlamydia pneumoniae as an emerging risk factor in cardiovascular disease. , 2002, JAMA.
[39] Kazuo Haze,et al. Neutrophil Infiltration of Culprit Lesions in Acute Coronary Syndromes , 2002, Circulation.
[40] S. Youssef,et al. The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease , 2002, Nature.
[41] P. Libby,et al. Stabilization of atherosclerotic plaques: New mechanisms and clinical targets , 2002, Nature Medicine.
[42] M. Gawaz,et al. A Critical Role of Platelet Adhesion in the Initiation of Atherosclerotic Lesion Formation , 2002, The Journal of experimental medicine.
[43] Jacob George,et al. Oral tolerance with heat shock protein 65 attenuates Mycobacterium tuberculosis-induced and high-fat-diet-driven atherosclerotic lesions. , 2002, Journal of the American College of Cardiology.
[44] P. Ridker,et al. Inflammatory bio‐markers and cardiovascular risk prediction , 2002, Journal of internal medicine.
[45] A. Sposito,et al. Statin Therapy in Acute Coronary Syndromes: Mechanistic Insight Into Clinical Benefit , 2002, Arteriosclerosis, thrombosis, and vascular biology.
[46] Qingbo Xu. Role of heat shock proteins in atherosclerosis. , 2002, Arteriosclerosis, thrombosis, and vascular biology.
[47] P. Libby,et al. Mucosal Administration of Heat Shock Protein-65 Decreases Atherosclerosis and Inflammation in Aortic Arch of Low-Density Lipoprotein Receptor-Deficient Mice , 2002, Circulation.
[48] J. Borén,et al. Subendothelial retention of atherogenic lipoproteins in early atherosclerosis , 2002, Nature.
[49] A. Daugherty,et al. IFN-gamma deficiency exerts gender-specific effects on atherogenesis in apolipoprotein E-/- mice. , 2002, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.
[50] M. Fishbein,et al. Overexpression of Interleukin-10 by Activated T Lymphocytes Inhibits Atherosclerosis in LDL Receptor–Deficient Mice by Altering Lymphocyte and Macrophage Phenotypes , 2002, Circulation research.
[51] J. Witztum. Splenic immunity and atherosclerosis: a glimpse into a novel paradigm? , 2002, The Journal of clinical investigation.
[52] G. Hansson,et al. Protective immunity against atherosclerosis carried by B cells of hypercholesterolemic mice. , 2002, The Journal of clinical investigation.
[53] G. Hansson,et al. Expression of Toll-Like Receptors in Human Atherosclerotic Lesions: A Possible Pathway for Plaque Activation , 2002, Circulation.
[54] S. Gordon,et al. Scavenger receptors in innate immunity. , 2002, Current opinion in immunology.
[55] J. Liao,et al. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors. , 2001, Arteriosclerosis, thrombosis, and vascular biology.
[56] A. Tedgui,et al. Interleukin-18/Interleukin-18 Binding Protein Signaling Modulates Atherosclerotic Lesion Development and Stability , 2001, Circulation research.
[57] E. Falk,et al. Dietary Supplementation With Methionine and Homocysteine Promotes Early Atherosclerosis but Not Plaque Rupture in ApoE-Deficient Mice , 2001, Arteriosclerosis, thrombosis, and vascular biology.
[58] S. Marx,et al. Bench to bedside: the development of rapamycin and its application to stent restenosis. , 2001, Circulation.
[59] L. Lindbom,et al. Importance of Primary Capture and L-Selectin–Dependent Secondary Capture in Leukocyte Accumulation in Inflammation and Atherosclerosis in Vivo , 2001, The Journal of experimental medicine.
[60] G. Hansson,et al. In vivo downregulation of T helper cell 1 immune responses reduces atherogenesis in apolipoprotein E-knockout mice. , 2001, Circulation.
[61] V. Emery,et al. Viral infections and their impact on chronic renal allograft dysfunction. , 2001, Transplantation.
[62] G. Hansson,et al. Chlamydia pneumoniae Infection Does Not Induce or Modify Atherosclerosis in Mice , 2001, Circulation.
[63] M. Burnett,et al. Cytomegalovirus infection increases development of atherosclerosis in Apolipoprotein-E knockout mice. , 2001, Atherosclerosis.
[64] P. Libby,et al. Macrophage myeloperoxidase regulation by granulocyte macrophage colony-stimulating factor in human atherosclerosis and implications in acute coronary syndromes. , 2001, The American journal of pathology.
[65] P. Shah,et al. Pravastatin Treatment Increases Collagen Content and Decreases Lipid Content, Inflammation, Metalloproteinases, and Cell Death in Human Carotid Plaques: Implications for Plaque Stabilization , 2001, Circulation.
[66] Anders Hamsten,et al. LDL Immunization Induces T-Cell–Dependent Antibody Formation and Protection Against Atherosclerosis , 2001, Arteriosclerosis, thrombosis, and vascular biology.
[67] F. Mach,et al. Statins as a newly recognized type of immunomodulator , 2000, Nature Medicine.
[68] A. Becker,et al. Unstable atherosclerotic plaques contain T-cells that respond to Chlamydia pneumoniae. , 2000, Cardiovascular research.
[69] M. Kurrer,et al. Linking immune-mediated arterial inflammation and cholesterol-induced atherosclerosis in a transgenic mouse model. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[70] A. Siegbahn,et al. Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease. FRISC Study Group. Fragmin during Instability in Coronary Artery Disease. , 2000, The New England journal of medicine.
[71] A. Maseri,et al. Evidence for Antigen-Driven T-Cell Response in Unstable Angina , 2000, Circulation.
[72] G Olivetti,et al. PTX3, A prototypical long pentraxin, is an early indicator of acute myocardial infarction in humans. , 2000, Circulation.
[73] R. Frye,et al. Monoclonal T-cell proliferation and plaque instability in acute coronary syndromes. , 2000, Circulation.
[74] P. Ridker,et al. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. , 2000, The New England journal of medicine.
[75] A. Quyyumi,et al. Effects of total pathogen burden on coronary artery disease risk and C-reactive protein levels. , 2000, The American journal of cardiology.
[76] Cecilia Soderberg-Naucler,et al. The Human Cytomegalovirus Chemokine Receptor US28 Mediates Vascular Smooth Muscle Cell Migration , 1999, Cell.
[77] M. Bureau,et al. Protective role of interleukin-10 in atherosclerosis. , 1999, Circulation research.
[78] K. Forfang,et al. Enhanced levels of soluble and membrane-bound CD40 ligand in patients with unstable angina. Possible reflection of T lymphocyte and platelet involvement in the pathogenesis of acute coronary syndromes. , 1999, Circulation.
[79] U. Andersson,et al. Cytokine expression in advanced human atherosclerotic plaques: dominance of pro-inflammatory (Th1) and macrophage-stimulating cytokines. , 1999, Atherosclerosis.
[80] S Marx,et al. Inhibition of intimal thickening after balloon angioplasty in porcine coronary arteries by targeting regulators of the cell cycle. , 1999, Circulation.
[81] G. Zhong,et al. The atherogenic effects of chlamydia are dependent on serum cholesterol and specific to Chlamydia pneumoniae. , 1999, The Journal of clinical investigation.
[82] R. Gaynor,et al. The anti-inflammatory agents aspirin and salicylate inhibit the activity of IκB kinase-β , 1998, Nature.
[83] I. Charo,et al. Decreased lesion formation in CCR2−/− mice reveals a role for chemokines in the initiation of atherosclerosis , 1998, Nature.
[84] P. Libby,et al. Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice. , 1998, Molecular cell.
[85] W. Koenig,et al. Activation of human aortic smooth-muscle cells is inhibited by PPARα but not by PPARγ activators , 1998, Nature.
[86] R. Ross,et al. Upregulation of VCAM-1 and ICAM-1 at atherosclerosis-prone sites on the endothelium in the ApoE-deficient mouse. , 1998, Arteriosclerosis, thrombosis, and vascular biology.
[87] P. Libby,et al. Activation of monocyte/macrophage functions related to acute atheroma complication by ligation of CD40: induction of collagenase, stromelysin, and tissue factor. , 1997, Circulation.
[88] A. Tall,et al. IFN-gamma potentiates atherosclerosis in ApoE knock-out mice. , 1997, The Journal of clinical investigation.
[89] Alan D. Lopez,et al. Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study , 1997, The Lancet.
[90] P. Ridker,et al. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. , 1997, The New England journal of medicine.
[91] A. Rebuzzi,et al. Plasma protein acute-phase response in unstable angina is not induced by ischemic injury. , 1996, Circulation.
[92] P. Kovanen,et al. TNF-alpha and IL-1beta selectively induce expression of 92-kDa gelatinase by human macrophages. , 1996, Journal of immunology.
[93] M J Davies,et al. Stability and instability: two faces of coronary atherosclerosis. The Paul Dudley White Lecture 1995. , 1996, Circulation.
[94] G. Ciliberto,et al. Elevated levels of interleukin-6 in unstable angina. , 1996, Circulation.
[95] L. Demer,et al. Cross-regulatory roles of interleukin (IL)-12 and IL-10 in atherosclerosis. , 1996, The Journal of clinical investigation.
[96] W D Wagner,et al. A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. , 1995, Arteriosclerosis, thrombosis, and vascular biology.
[97] P. Constantinides. Infiltrates of activated mast cells at the site of coronary atheromatous erosion or rupture in myocardial infarction. , 1995, Circulation.
[98] Michael Ginsberg,et al. Decreased atherosclerosis in mice deficient in both macrophage colony-stimulating factor (op) and apolipoprotein E. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[99] V. Fuster,et al. Coronary plaque disruption. , 1995, Circulation.
[100] Y. Bobryshev,et al. Ultrastructural recognition of cells with dendritic cell morphology in human aortic intima. Contacting interactions of Vascular Dendritic Cells in athero-resistant and athero-prone areas of the normal aorta. , 1995, Archives of histology and cytology.
[101] J. Witztum,et al. T lymphocytes from human atherosclerotic plaques recognize oxidized low density lipoprotein. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[102] E. Miller,et al. Immunization of low density lipoprotein (LDL) receptor-deficient rabbits with homologous malondialdehyde-modified LDL reduces atherogenesis. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[103] A. Rebuzzi,et al. The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina. , 1994, The New England journal of medicine.
[104] V. Fuster,et al. Macrophage Infiltration in Acute Coronary Syndromes: Implications for Plaque Rupture , 1994, Circulation.
[105] W D Wagner,et al. A definition of initial, fatty streak, and intermediate lesions of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. , 1994, Arteriosclerosis and thrombosis : a journal of vascular biology.
[106] G. Hansson,et al. Immune mechanisms in atherosclerosis. , 1994, Coronary artery disease.
[107] P. Libby,et al. Cytokines and growth factors positively and negatively regulate interstitial collagen gene expression in human vascular smooth muscle cells. , 1991, Arteriosclerosis and thrombosis : a journal of vascular biology.
[108] M. Cybulsky,et al. Endothelial expression of a mononuclear leukocyte adhesion molecule during atherogenesis. , 1991, Science.
[109] G. Gabbiani,et al. Interferon gamma inhibits both proliferation and expression of differentiation-specific alpha-smooth muscle actin in arterial smooth muscle cells , 1989, The Journal of experimental medicine.
[110] G. Hansson,et al. Detection of activated T lymphocytes in the human atherosclerotic plaque. , 1989, The American journal of pathology.
[111] J. Mehta,et al. Neutrophil function in ischemic heart disease. , 1989, Circulation.
[112] A. Maseri,et al. Pre-existing coronary stenoses in patients with first myocardial infarction are not necessarily severe. , 1988, European heart journal.
[113] M. Nieminen,et al. SEROLOGICAL EVIDENCE OF AN ASSOCIATION OF A NOVEL CHLAMYDIA, TWAR, WITH CHRONIC CORONARY HEART DISEASE AND ACUTE MYOCARDIAL INFARCTION , 1988, The Lancet.
[114] G. Hansson,et al. Cyclosporin A inhibits smooth muscle proliferation in the vascular response to injury. , 1988, Proceedings of the National Academy of Sciences of the United States of America.
[115] G. Bondjers,et al. Regional Accumulations of T Cells, Macrophages, and Smooth Muscle Cells in the Human Atherosclerotic Plaque , 1986, Arteriosclerosis.
[116] L. Wilhelmsen,et al. Fibrinogen as a risk factor for stroke and myocardial infarction. , 1984, The New England journal of medicine.
[117] A. Siegelaub,et al. The leukocyte count as a predictor of myocardial infarction. , 1974, The New England journal of medicine.
[118] R. Flavell,et al. Disruption of TGF-beta signaling in T cells accelerates atherosclerosis. , 2003, The Journal of clinical investigation.
[119] J. Michel,et al. Interleukin-10 Deficiency Increases Atherosclerosis, Thrombosis, and Low-density Lipoproteins in Apolipoprotein E Knockout Mice , 2003, Molecular medicine.
[120] C. Janeway,et al. Innate immune recognition. , 2002, Annual review of immunology.
[121] W. Koenig,et al. Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPARgamma activators. , 1998, Nature.
[122] J. D. Smith,et al. Mouse models of atherosclerosis. , 1998, Laboratory animal science.
[123] A. Becker,et al. Site of intimal rupture or erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque morphology. , 1994, Circulation.